Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

US Patent 11141436 · Granted Oct 12, 2021

Estimated economic value: $12,887,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Genetically modified natural killer cells for CD70-directed cancer immunotherapy2024
Genetically modified natural killer cells for CD70-directed cancer immunotherapy2024